Form 8-K BIOGEN INC. For: Apr 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
April 22, 2020 10:12 AM EDTSunTrust analyst Robyn Karnauskas reiterated a Buy rating and $360.00 price target on Biogen (NASDAQ: BIIB), telling clients to 'buy on weakness'
Karnauskas notes the company updated their Alzheimer's Disease (AD) filing timelines from early 2020 to a rolling BLA, with completion by 3Q20,... More
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... More